02.09.2022 – The CLEVER-ACS randomized clinical trial was published in the Journal of the American College of Cardiology (Randomized Trial of Early mTOR Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction).
CLEVER-ACS was a randomized, multicenter, international, double-blind, placebo-controlled trial. CLEVER-ACS investigated whether mTOR inhibition using everolimus in patients with ST-elevation Myocardial infarction undergoing percutaneous coronary intervention (e.g. stenting) could reduce myocardial infarct (MI) size and improve left ventricular remodeling, compared to a placebo treatment. A total of 150 patients were randomized to either receive oral everolimus for 5 days or receive placebo for 5 days. The primary endpoint was the change in myocardial infarct size from baseline (12h to 5 days after PCI) to 30 days as assessed by cardiac magnetic resonance imaging (CMR) using a core laboratory. The everolimus and placebo groups did not differ comparing both the primary and secondary endpoints, as both groups showed a similar reduction in MI size after 30 days.
See for full details: https://www.jacc.org/doi/abs/10.1016/j.jacc.2022.08.747
CTU Bern was involved in the planning, data management and statistical analyses of the trial.